NASDAQ$DERM
Journey Medical Corp · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Announced third quarter 2024 financial results with revenue of $14.6 million and highlighted the FDA approval of Emrosi™ for rosacea treatment.
Journey Medical reported solid third quarter 2024 results with total revenues of $14.6 million and highlighted the FDA approval of Emrosi™ for the treatment of inflammatory lesions of rosacea in adults, with launch expected in late Q1 or early Q2 of 2025.
- U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults.
- The launch of Emrosi is expected in late Q1 or early Q2 of 2025.
- Total revenues for the third quarter ended September 30, 2024, were $14.6 million.
- The company is completing manufacturing activities and deploying its sales force to enable patient access to Emrosi.
Headline financials
Revenue & EPS history
Journey Medical · Revenue · Quarterly
$14.6M
Forward guidance
The company anticipates continued growth with the expected launch of Emrosi in late first quarter or early second quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-2.3%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+3.7%
Avg return
30 days after
41%
9 / 22 earnings
Positive
+22.0%
Q1 2025
Best reaction
-26.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.0% | +24.4% | — | |
| Q4 2025 | -26.8% | -31.3% | -24.6% | |
| Q3 2025 | -15.3% | -12.4% | -15.5% | |
| Q1 2025 | +22.0% | +15.2% | +13.6% | |
| Q4 2024 | -3.6% | -2.8% | +21.7% | |
| Q3 2024 | -8.2% | -7.5% | -9.3% | |
| Q2 2024 | -3.2% | -11.0% | -3.8% | |
| Q1 2024 | +2.8% | -1.7% | +69.2% | |
| Q4 2023 | -14.1% | -3.9% | -9.4% | |
| Q3 2023 | +15.7% | +14.8% | +105.5% | |
| Q2 2023 | +14.0% | +4.7% | +21.5% | |
| Q1 2023 | -10.1% | -23.2% | +44.9% | |
| Q4 2022 | +3.1% | +13.1% | +26.3% | |
| Q3 2022 | -8.7% | -9.2% | -27.2% | |
| Q2 2021 | -4.3% | -7.0% | -30.1% | |
| Q2 2022 | -4.3% | -7.0% | -30.1% | |
| Q1 2022 | -12.3% | +5.1% | +0.8% | |
| Q1 2021 | -12.3% | +5.1% | +0.8% | |
| Q4 2021 | +5.4% | +6.1% | -1.8% | |
| Q3 2020 | +3.4% | -0.1% | -24.3% | |
| Q4 2020 | +3.4% | -0.1% | -24.3% | |
| Q3 2021 | +0.0% | +0.0% | -25.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro